SBT 11 5301
Alternative Names: SBT-11-5301; SBT-115301 - Sonoma BiotherapeuticsLatest Information Update: 18 Aug 2022
At a glance
- Originator Sonoma Biotherapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Recombinant fusion proteins
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 25 Jul 2022 Phase-I clinical trials in Type 1 diabetes mellitus (In volunteers) in USA (Parenteral) (NCT05388981)
- 08 Jun 2022 US FDA approves IND application for SBT 11 5301 for a phase I study in Healthy participants
- 19 May 2022 Sonoma Biotherapeutics plans a phase I trial in healthy volunteers (NCT05388981)